Drug patents: the evergreening problem.
作者信息
Collier Roger
出版信息
CMAJ. 2013 Jun 11;185(9):E385-6. doi: 10.1503/cmaj.109-4466. Epub 2013 Apr 29.
Abstract
摘要
相似文献
1
Drug patents: the evergreening problem.药品专利：专利期限延长问题。
CMAJ. 2013 Jun 11;185(9):E385-6. doi: 10.1503/cmaj.109-4466. Epub 2013 Apr 29.
2
Limiting "evergreening" for a better balance of drug innovation incentives.限制“常青化”以更好地平衡药物创新激励措施。
CMAJ. 2013 Aug 6;185(11):939. doi: 10.1503/cmaj.130992. Epub 2013 Jul 22.
3
Drug patents: innovation v. accessibility.药品专利：创新与可及性的权衡
CMAJ. 2013 Jun 11;185(9):E379-80. doi: 10.1503/cmaj.109-4465. Epub 2013 Apr 29.
4
India's patent laws under pressure.
Lancet. 2012 Sep 15;380(9846):e2-4. doi: 10.1016/s0140-6736(12)61513-x.
5
How Patent Troll Legislation Can Increase Timely Access to Generic Drugs.
JAMA Intern Med. 2016 Jun 1;176(6):729-30. doi: 10.1001/jamainternmed.2016.1867.
6
Supreme Court rules against drug patent "evergreening".最高法院做出不利于药品专利“常青化”的裁决。
CMAJ. 2006 Dec 5;175(12):1508-9. doi: 10.1503/cmaj.061513.
7
A generic problem.一个一般性问题。
Nat Clin Pract Gastroenterol Hepatol. 2006 Dec;3(12):649. doi: 10.1038/ncpgasthep0659.
8
Intellectual property. Challenges to India's pharmaceutical patent laws.知识产权。印度制药专利法面临的挑战。
Science. 2012 Jul 27;337(6093):414-5. doi: 10.1126/science.1224892. Epub 2012 Jul 5.
9
Taking TRIPS to India--Novartis, patent law, and access to medicines.前往印度的《与贸易有关的知识产权协定》之行——诺华公司、专利法与药品可及性
N Engl J Med. 2007 Feb 8;356(6):541-3. doi: 10.1056/NEJMp068245.
10
Patents: a threat to innovation?专利：对创新的威胁？
Science. 2010 Jan 1;327(5961):31-2; author reply 32. doi: 10.1126/science.327.5961.31.
引用本文的文献
1
Safety and efficacy of long-acting cabotegravir/rilpivirine versus standard oral antiretroviral therapy: a systematic review and meta-analysis.长效卡博特韦/利匹韦林对比标准口服抗逆转录病毒疗法的安全性和有效性：一项系统评价与荟萃分析
J Antimicrob Chemother. 2025 Mar 3;80(3):624-632. doi: 10.1093/jac/dkae480.
2
Some Aspects and Convergence of Human and Veterinary Drug Repositioning.人类和兽医药物再定位的一些方面和趋同。
Molecules. 2024 Sep 20;29(18):4475. doi: 10.3390/molecules29184475.
3
Patent and Marketing Exclusivities 101 for Drug Developers.药物开发者专利和营销专有权 101。
Recent Pat Biotechnol. 2023;17(3):257-270. doi: 10.2174/1872208317666230111105223.
4
Comparison of Pharmaceutical Characteristics between Brand-Name Meropenem and Its Generics.原研美罗培南与其仿制药的药学特性比较。
Antibiotics (Basel). 2021 Sep 10;10(9):1096. doi: 10.3390/antibiotics10091096.
5
Two-drug fixed-dose combinations of blood pressure-lowering drugs as WHO essential medicines: An overview of efficacy, safety, and cost.两种降压药物的固定剂量复方制剂作为世界卫生组织基本药物：疗效、安全性和成本概述。
J Clin Hypertens (Greenwich). 2020 Oct;22(10):1769-1779. doi: 10.1111/jch.14009. Epub 2020 Aug 20.
6
The complex legal and ethical issues related to generic medications. Viral hepatitis: a case study.与仿制药相关的复杂法律和伦理问题。病毒性肝炎：一个案例研究。
J Virus Erad. 2017 Apr 1;3(2):77-81. doi: 10.1016/S2055-6640(20)30286-7.
7
Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine.纳米金刚石：纳米技术、药物研发与个性化医疗的交叉领域。
Sci Adv. 2015 Aug 21;1(7):e1500439. doi: 10.1126/sciadv.1500439. eCollection 2015 Aug.
8
Limiting "evergreening" for a better balance of drug innovation incentives.限制“常青化”以更好地平衡药物创新激励措施。
CMAJ. 2013 Aug 6;185(11):939. doi: 10.1503/cmaj.130992. Epub 2013 Jul 22.
Zotero 插件